- Phase IV data strengthen case for Toviaz in competitive overactive bladder market
- US approval sets up Astellas' overactive bladder drug for second launch
- US FDA warns of unapproved, phony Botox
- EU's CHMP positive on Astellas' mirabegron
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.